drugset / Trial / NCT02370121

Effect of Gymnema Sylvestre on Metabolic Syndrome and Insulin

NCT02370121 ↗

Phase 2 Completed 24 enrolled University of Guadalajara
RandomizedParallel-groupTriple-blindTreatment

Summary

Gymnema sylvestre has demonstrated promising effects in the treatment of obesity, dyslipidemia, hypertension, insulin secretion, among others. The above mentioned findings show that Gymnema sylvestre has an excellent potential for the prevention and treatment of metabolic syndrome.

Timeline

Start
2013-02
Primary completion
2014-12
Completion
2015-01

Outcome

Missed primary endpoint

registry analysis (superiority or other test); Placebo vs Gymnema Sylvestre; p = 0.57; Wilcoxon (Mann-Whitney) NCT02370121 ↗

registry analysis (superiority or other test); Placebo vs Gymnema Sylvestre; p = 0.07; Wilcoxon (Mann-Whitney) NCT02370121 ↗

registry analysis (superiority or other test); Placebo vs Gymnema Sylvestre; p = 0.79; Wilcoxon (Mann-Whitney) NCT02370121 ↗

registry analysis (superiority or other test); Placebo vs Gymnema Sylvestre; p = 0.08; Wilcoxon (Mann-Whitney) NCT02370121 ↗

registry analysis (superiority or other test); Placebo vs Gymnema Sylvestre; p = 0.95; Wilcoxon (Mann-Whitney) NCT02370121 ↗

registry analysis (superiority or other test); Placebo vs Gymnema Sylvestre; p = 0.92; Wilcoxon (Mann-Whitney) NCT02370121 ↗

registry analysis (superiority or other test); Placebo vs Gymnema Sylvestre; p = 0.42; Wilcoxon (Mann-Whitney) NCT02370121 ↗

registry analysis (superiority or other test); Placebo vs Gymnema Sylvestre; p = 0.77; Wilcoxon (Mann-Whitney) NCT02370121 ↗

registry analysis (superiority or other test); Placebo vs Gymnema Sylvestre; p = 0.17; Wilcoxon (Mann-Whitney) NCT02370121 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Gymnema Sylvestre Traditional medicine (herbal / TCM) 300 mg Oral

Indications